IDEXX Laboratories (NASDAQ:IDXX) EVP Sells $3,369,657.98 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Michael Erickson sold 5,371 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

IDEXX Laboratories Trading Down 0.7%

Shares of NASDAQ:IDXX traded down $4.17 during mid-day trading on Thursday, reaching $630.73. 307,461 shares of the company’s stock were exchanged, compared to its average volume of 506,699. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The firm has a market capitalization of $50.36 billion, a price-to-earnings ratio of 48.26, a PEG ratio of 3.81 and a beta of 1.67. The business’s fifty day moving average price is $680.64 and its 200-day moving average price is $669.42.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business earned $2.53 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the business. Empowered Funds LLC raised its holdings in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories in the 2nd quarter worth about $265,000. Harbour Investments Inc. increased its stake in IDEXX Laboratories by 27.3% in the 2nd quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock valued at $53,000 after buying an additional 21 shares during the last quarter. Mutual Advisors LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $244,000. Finally, Nordea Investment Management AB boosted its stake in shares of IDEXX Laboratories by 4.7% in the 2nd quarter. Nordea Investment Management AB now owns 8,057 shares of the company’s stock worth $4,298,000 after buying an additional 361 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IDXX shares. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Barclays dropped their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Piper Sandler dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.